New progress in the study of poly (L-glutamic acid)-paclitaxel conjugates for cancer treatment

Abstract

Abstract: The preparation of polymer-anticancer drug conjugates is an effective way to improve the efficacy and decrease the toxicity of anticancer drugs. Polymer-drug conjugates, which were made by combining a suitable polymeric carrier, a biodegradable linker and a bioactive anticancer agent, could form the basis of a new generation of anticancer agents. Poly (L-glutamic acid)-paclitaxel conjugate is a polymer-drug conjugate that links anticancer agent paclitaxel (PTX) to poly (L-glutamic acid) (PG). PG-PTX conjugate can improve the anticancer activity, enhance the safety and efficacy, and improve the pharmacokinetic properties of PTX. Therefore, the application of PG-PTX facilitates the clinical therapy of a variety of human cancers.

Key words: Paclitaxel, Paclitaxel, Poly (L-glutamic acid)-paclitaxel conjugate, Poly (L-glutamic acid)-paclitaxel conjugate, Pharmacokinetics, Pharmacokinetics

CLC Number:

R969.1

Supporting:

Yi-Ning Song, Shuang-Qing Zhang^*, Zhen-Qing Zhang^*. New progress in the study of poly (L-glutamic acid)-paclitaxel conjugates for cancer treatment [J]. .

References

[1] Kim, C.K.; Lim, S.J. Arch. Pharm. Res. 2002, 25, 229-239.
[2] Sugahara, S.; Kajiki, M.; Kuriyama, H.; Kobayashi, T.R. Control Release. 2007, 117, 40-50.
[3] Haag, R.; Kratz, F. Angew. Chem (Int. Ed. Engl). 2006, 45, 1198-1215.
[4] Rowinsky, E.K. Annu. Rev. Med. 1997, 48, 353-374.
[5] Bhalla, K.N. Oncogene. 2003, 22, 9075-9086.
[6] Parveen, S.; Sahoo, S.K. Drug Target. 2008, 16, 108-123.
[7] Ten Tije, A.J.; Verweij, J.; Loos, W.J.; Sparreboom, A. Clin Pharmacokinet. 2003, 42, 665-685.
[8] Rogers, B.B. Oncol. Nurs. 1993, 20, 1483-1489.
[9] Price, K.S.; Castells, M.C. Allergy Asthma. Proc. 2002, 23, 205-208.
[10] Lemieux, J.; Maunsell, E.; Provencher, L. Psychooncology. 2008, 17, 317-328.
[11] Singer, J.W. Control. Release. 2005, 109, 120-126.
[12] Luo, Y.; Prestwich, G.D. Curr. Cancer Drug Targets. 2002, 2, 209-226.
[13] Greco, F.; Vicent, M.J. Front. Biosci. 2008, 13, 2744-2756.
[14] Li, C. Adv. Drug Deliv. Rev. 2002, 54, 695-713.
[15] Roberts, W.G.; Palade, G.E. Cancer Res. 1997, 57, 765-772.
[16] Reddy, L.H. Pharm. Pharmacol. 2005, 57, 1231-1242.
[17] Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Control Release. 2000, 65, 271-284.
[18] Iyer, A.K.; Greish, K.; Seki, T.; Okazaki, S.; Fang, J.; Takeshita, K.; Maeda, H. Drug Target. 2007, 15, 496-506.
[19] Boddy, A.V.; Plummer, E.R.; Todd, R.; Sludden, J.; Griffin, M.; Robson, L.; Cassidy, J.; Bissett, D.; Bernareggi, A.; Verrill, M.W.; Calvert, A.H. Clin. Cancer Res. 2005, 11, 7834-7840.
[20] Greish, K.; Fang, J.; Inutsuka, T.; Nagamitsu, A.; Maeda, H. Clin. Pharmacokinet. 2003, 42, 1089-1105.
[21] Shaffer, S.A.; Baker, L.C.; Kennedy, J.; Lai, M.S.; de Vries, P.; Buhler, K.; Singer, J.W. Cancer Chemother Pharmacol. 2007, 59, 537-548.
[22] Maeda, H.; Bharate, G.Y.; Daruwalla, J. Eur. J. Pharm. Biopharm. 2009, 71, 409-419.
[23] Kim, T.Y.; Kim, D.W.; Chung, J.Y.; Shin, S.G.; Kim, S.C.; Heo, D.S.; Kim, N.K.; Bang, Y.J. Clin. Cancer Res. 2004, 10, 3708-3716.
[24] Ibrahim, N.K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R.L.; Rivera, E.; Esmaeli, B.; Ring, S.E.; Bedikian, A.; Hortobagyi, G.N.; Ellerhorst, J.A. Clin. Cancer Res. 2002, 8, 1038-1044.
[25] Soepenberg, O.; Sparreboom, A.; de Jonge, M.J.; Planting, A.S.; de Heus, G.; Loos, W.J.; Hartman, C.M.; Bowden, C.; Verweij, J. Eur. J. Cancer. 2004, 40, 681-688.
[26] Li, C.; Yu, D.; Inoue, T.; Yang, D.J.; Milas, L.; Hunter, N.R.; Kim, E.E.; Wallace, S. Anti Cancer Drugs. 1996, 7, 642-648.
[27] Bonomi, P. Expert Rev. Anticancer Ther. 2007, 7, 415-422.
[28] Multani, A.S.; Li, C.; Ozen, M.; Imam, A.S.; Wallace, S.; Pathak, S. Oncol. Rep. 1999, 6, 39-44.
[29] Turk, V.; Turk, B.; Turk, D. EMBO J. 2001, 20, 4629-4633.
[30] Podgorski, I.; Sloane, B.F. Biochem. Soc. Symp. 2003, 70, 263-276.
[31] Sabbatini, P.; Aghajanian, C.; Dizon, D.; Anderson, S.; Dupont J.; Brown, J.V.; Peters, W.A.; Jacobs, A.; Mehdi, A.; Rivkin, S.; Eisenfeld, A.J.; Spriggs, D. J Clin Oncol. 2004, 22, 4523-4531.
[32] Mita, M.; Mita, A.; Sarantopoulos, J.; Takimoto, C.H.; Rowinsky, E.K.; Romero, O.; Angiuli, P.; Allievi, C.; Eisenfeld, A.; Verschraegen, C.F. Cancer Chemother. Pharmacol. 2009, 64, 287-295.
[33] Li, C.; Yu, D.F.; Newman, R.A.; Cabral, F.; Stephens, L.C.; Hunter, N.; Milas, L.; Wallace, S. Cancer Res. 1998, 58, 2404-2409.
[34] Li, C.; Price, J.E.; Milas, L.; Hunter, N.R.; Ke, S.; Yu, D.F.; Charnsangavej, C.; Wallace, S. Clin. Cancer Res. 1999, 5, 891-897.
[35] Verschraegen, C.F.; Skubitz, K.; Daud, A.; Kudelka, A.P.; Rabinowitz, I.; Allievi, C.; Eisenfeld, A.; Singer, J.W.; Oldham, F.B. Cancer Chemother. Pharmacol. 2009, 63, 903-910.
[36] Li, C.; Newman, R.A.; Wu, Q.P.; Ke, S.; Chen, W.; Hutto, T.; Kan, Z. Cancer Chemother. Pharmacol. 2000, 46, 416-422.
[37] Oldham, E.A.; Li, C.; Ke, S.; Wallace, S.; Huang, P. Int. J. Oncol. 2000, 16, 125-132.
[38] Chipman, S.D.; Oldham, F.B.; Pezzoni, G.; Singer, J.W. Int. J. Nanomedicine. 2006, 1, 375-383.
[39] Todd, R.; Sludden, J.; Boddy, A.V.; Grifﬁn, M.J.; Robson, L.; Cassidy, J.; Bissett, D.; Main, M.; Brannan, M.D.; Elliott, S.; Fishwick, K.; Verrill, M.; Calvert. H. ASCO. 2001 (abstract 439).
[40] Milas, L.; Mason, K.A.; Hunter, N.; Li, C.; Wallace, S. Int. J. Radiat. Oncol. Biol. Phys. 2003, 55, 707-712.
[41] Li, C.; Ke, S.; Wu, Q.P.; Tansey, W.; Hunter, N.; Buchmiller, L.M.; Milas, L.; Charnsangavej, C.; Wallace, S. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 1119-1126.
[42] Li, C.; Ke, S.; Wu, Q.P.; Tansey, W.; Hunter, N.; Buchmiller, L.M.; Milas, L.; Charnsangavej, C.; Wallace, S. Clin. Cancer Res. 2000, 6, 2829-2834.
[43] Sabbatini, P.; Aghajanian, C.; Dizon, D. Clin. Oncol. 2004, 22, 4523-4530.
[44] Vicent, M.J.; Dieudonné, L.; Carbajo, R.J.; Pineda-Lucena, A. Expert. Opin. Drug Deliv. 2008, 5, 593-614.